// App-Quantinova.ai

: Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models

Researchers

Presenter

  • Matthias Eder

Principal Investigators

  • Hanna Kirchhoff

  • Karin Battmer

  • Katharina Wohlan

  • Melanie Ricke-Hoch

  • Sergej Erschow

  • Edward Law

  • Arnold Kloos

  • Michael Heuser

  • Arnold Ganser

  • Denise Hilfiker-Kleiner

  • Olaf Heidenreich

  • Michaela Scherr

Medical Centers

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Hannover Medical School, Hannover, Germany

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Myeloid Cell Leukemia 1

  • B-cell lymphoma 2

  • BCL2 like 11

  • Breakpoint Cluster Region

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Venetoclax

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved